Marie Pierre Audrézet1, Anne Munck2, Virginie Scotet3, Mireille Claustres4, Michel Roussey5, Dominique Delmas6, Claude Férec7, Marie Desgeorges4. 1. 1] Laboratoire de Génétique Moléculaire et d'Histocompatibilité, CHU de Brest, Brest, France [2] INSERM U1078, Brest, France. 2. 1] Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant, Paris, France [2] CRCM-Service de Gastro-Entérologie-Mucoviscidose et Nutrition Pédiatriques, Université Paris 7, Hôpital Robert Debré, Paris, France. 3. 1] INSERM U1078, Brest, France [2] Université de Bretagne Occidentale, Brest, France [3] Etablissement Français du Sang-Bretagne, Brest, France. 4. 1] Laboratoire de Génétique Moléculaire, IURC, CHU de Montpellier, Montpellier, France [2] INSERM U827, Laboratoire de Génétique des Maladies Rares, Montpellier, France [3] Université Montpellier 1, UFR de Médecine, Montpellier, France. 5. 1] Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant, Paris, France [2] CRCM-Département de Médecine de l'Enfant et de l'Adolescent, CHU de Rennes-Hôpital Sud, Rennes, France. 6. Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant, Paris, France. 7. 1] Laboratoire de Génétique Moléculaire et d'Histocompatibilité, CHU de Brest, Brest, France [2] INSERM U1078, Brest, France [3] Université de Bretagne Occidentale, Brest, France [4] Etablissement Français du Sang-Bretagne, Brest, France.
Abstract
PURPOSE: Newborn screening (NBS) for cystic fibrosis (CF) was implemented throughout France in 2002. It involves a four-tiered procedure: immunoreactive trypsin (IRT)/DNA/IRT/sweat test [corrected] was implemented throughout France in 2002. The aim of this study was to assess the performance of molecular CFTR gene analysis from the French NBS cohort, to evaluate CF incidence, mutation detection rate, and allelic heterogeneity. METHODS: During the 8-year period, 5,947,148 newborns were screened for cystic fibrosis. The data were collected by the Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant. The mutations identified were classified into four groups based on their potential for causing disease, and a diagnostic algorithm was proposed. RESULTS: Combining the genetic and sweat test results, 1,160 neonates were diagnosed as having cystic fibrosis. The corresponding incidence, including both the meconium ileus (MI) and false-negative cases, was calculated at 1 in 4,726 live births. The CF30 kit, completed with a comprehensive CFTR gene analysis, provides an excellent detection rate of 99.77% for the mutated alleles, enabling the identification of a complete genotype in 99.55% of affected neonates. With more than 200 different mutations characterized, we confirmed the French allelic heterogeneity. CONCLUSION: The very good sensitivity, specificity, and positive predictive value obtained suggest that the four-tiered IRT/DNA/IRT/sweat test procedure may provide an effective strategy for newborn screening for cystic fibrosis.
PURPOSE: Newborn screening (NBS) for cystic fibrosis (CF) was implemented throughout France in 2002. It involves a four-tiered procedure: immunoreactive trypsin (IRT)/DNA/IRT/sweat test [corrected] was implemented throughout France in 2002. The aim of this study was to assess the performance of molecular CFTR gene analysis from the French NBS cohort, to evaluate CF incidence, mutation detection rate, and allelic heterogeneity. METHODS: During the 8-year period, 5,947,148 newborns were screened for cystic fibrosis. The data were collected by the Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant. The mutations identified were classified into four groups based on their potential for causing disease, and a diagnostic algorithm was proposed. RESULTS: Combining the genetic and sweat test results, 1,160 neonates were diagnosed as having cystic fibrosis. The corresponding incidence, including both the meconium ileus (MI) and false-negative cases, was calculated at 1 in 4,726 live births. The CF30 kit, completed with a comprehensive CFTR gene analysis, provides an excellent detection rate of 99.77% for the mutated alleles, enabling the identification of a complete genotype in 99.55% of affected neonates. With more than 200 different mutations characterized, we confirmed the French allelic heterogeneity. CONCLUSION: The very good sensitivity, specificity, and positive predictive value obtained suggest that the four-tiered IRT/DNA/IRT/sweat test procedure may provide an effective strategy for newborn screening for cystic fibrosis.
Authors: Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon Journal: Eur J Hum Genet Date: 2008-08-06 Impact factor: 4.246
Authors: Kevin W Southern; Anne Munck; Rodney Pollitt; Georges Travert; Luisa Zanolla; Jeannette Dankert-Roelse; Carlo Castellani Journal: J Cyst Fibros Date: 2006-07-25 Impact factor: 5.482
Authors: Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn Journal: N Engl J Med Date: 2011-11-03 Impact factor: 91.245
Authors: C Thauvin-Robinet; A Munck; F Huet; E Génin; G Bellis; E Gautier; M-P Audrézet; C Férec; G Lalau; M Des Georges; M Claustres; T Bienvenu; B Gérard; P Boisseau; F Cabet-Bey; D Feldmann; C Clavel; E Bieth; A Iron; B Simon-Bouy; C Costa; R Medina; J Leclerc; D Hubert; R Nové-Josserand; I Sermet-Gaudelus; G Rault; J Flori; S Leroy; N Wizla; G Bellon; A Haloun; S Perez-Martin; G d'Acremont; H Corvol; A Clément; E Houssin; C Binquet; C Bonithon-Kopp; C Alberti-Boulmé; M A Morris; L Faivre; M Goossens; M Roussey; E Girodon Journal: J Med Genet Date: 2009-06-29 Impact factor: 6.318
Authors: Lisa Prach; Ruth Koepke; Martin Kharrazi; Steven Keiles; Danieli B Salinas; Maria Carmen Reyes; Mark Pian; Harry Opsimos; Kimberly N Otsuka; Karen Ann Hardy; Carlos E Milla; Jacquelyn M Zirbes; Bradley Chipps; Susan O'Bra; Muhammad M Saeed; Reddivalam Sudhakar; Susan Lehto; Dennis Nielson; Gregory F Shay; Mary Seastrand; Sanjay Jhawar; Bruce Nickerson; Christopher Landon; Ann Thompson; Eliezer Nussbaum; Terry Chin; Henry Wojtczak Journal: J Mol Diagn Date: 2013-06-28 Impact factor: 5.568
Authors: Cecilia Catellani; Francesca Cirillo; Sara Graziano; Luisa Montanini; Nelson Marmiroli; Mariolina Gullì; Maria Elisabeth Street Journal: Acta Biomed Date: 2022-07-01